FDA Recall Levothyroxine Sodium

The last Recall Enforcement Report for Levothyroxine Sodium with NDC 47781-657 was initiated on 02-06-2023 as a Class II recall due to sub-potent drug: out of specification for assay at the 24 month interval. The latest recall number for this product is D-0353-2023 and the recall is currently terminated as of 03-18-2024 .

Recall Number D-0353-2023

Field Name	Field Value
Event ID	91654 What is the Event ID? A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number	D-0353-2023 What is the Recall Number? An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification	Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification? Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern	Nationwide and Puerto Rico. What is the Distribution Pattern? General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description	Levothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle, Rx Only, Manufactured by Lloyd Inc., Shenandoah, IA, 51601, Distributed by: Alvogen Inc, Pine Brook, NJ 07058, NDC 47781-654-90.
Reason For Recall	Sub-Potent Drug: Out of specification for assay at the 24 month interval. What is the Reason for Recall? Information describing how the product is defective.
Product Quantity	21,276 bottles Product Quantity The amount of product subject to recall.
Voluntary Mandated	Voluntary: Firm initiated Voluntary / Mandated Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date	03-08-2023
Recall Initiation Date	02-06-2023 What is the Recall Initiation Date? The date that the firm first began notifying the public or their consignees of the recall.
Termination Date	03-18-2024 What is the Date Terminated? The date that FDA terminated the recall.
Initial Firm Notification	Letter Initial Firm Notification of Consignee or Public The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type	Drugs
Recalling Firm	Alvogen, Inc
Code Info	Lot # HE02221, Exp. 05/2023 Code Information A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages	47781-640-90; 47781-640-10; 47781-643-90; 47781-643-10; 47781-646-90; 47781-646-10; 47781-649-90; 47781-649-10; 47781-651-90; 47781-651-10; 47781-654-90; 47781-654-10; 47781-657-90; 47781-657-10; 47781-659-90; 47781-659-10; 47781-662-90; 47781-662-10; 47781-665-90; 47781-665-10; 47781-668-90; 47781-668-10; 47781-671-90; 47781-671-10
Status	Terminated - A recall where FDA has determined that all reasonable efforts have been made to remove or correct the violative product in accordance with the recall strategy, and proper disposition has been made according to the degree of hazard.
	View Recall Report

What is the Enforcement Report?

All drug recalls are monitored by the Food and Drug Administration (FDA) and are included in the Enforcement Report once they are properly classified. The FDA will determine if a firm's removal or correction actions of a marked product meet the requirements to be considered a "recall". The FDA will also determine the public hazard assessment and a recall classification will be published in the Enforcement Report.